Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1994-06-17
1995-11-28
Springer, David B.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514604, A61K 31405, A61K 3118
Patent
active
054708702
ABSTRACT:
The present invention is directed to a class of 4,6-disubstituted tryptophan derivatives, 4,6-disubstituted kynurenines, their use as NMDA antagonists and to pharmaceutical compositions containing these compounds.
REFERENCES:
patent: 3445479 (1969-05-01), Hydorn
patent: 4140697 (1979-02-01), Batcho et al.
The Journal of Neuroscience, Sep. 1990, 10(9):2965-297: Cerebral Synthesis and Release of Kynurenic Acid: an Endogenous Antagonist of Excitatory Amino Acid Receptors.
Society For Neuroscience Abstracts, vol. 17, 1991; 315.3; Systemic Loading with Kynurenine and Probenecid Markedly increases Striatal Kynurenic Acid Levels as Measured by In Vivo Microialysis, Miller, et al.
Chemical Abstracts 112(7): 52836c; Uptake of kynurenine into rat brain slices, Speciale, et al. (1990).
Chemical Abstracts 76(25): 150339a:Enzymic studies of the biosynthesis of 5-hydroxy-L-kynurenine in the rat small intestine, Konishi (1972).
Chemial Abstracts 75(3): 17141t; Pyrrole ring cleavaging enzyme of 5-hydroxytryptophan, Konishi, et al. (1971).
Chemical Abstracts 69(9):33829e; Formation of 5-hydroxy-L-kynurenine from L-kynurenine by hen liver microsomes; Kido, et al. 1968.
Chemical Abstracts 72(3)9673r; Influence of androgens on tryptophan metabolism in man, McGinty, et al. (1970).
Chemical Abstracts 74(21): 107987g; Gas, chromatographic analysis of tryptophan metabolites, Noguchi et al. (1971).
Chemical Abstracts 72(21): 107236v; 5-Hydroxykynurenine decarboxylase in rat intestine, Noguchi, et al (1970).
Chemical Abstracts 67(21):96860n; Metabolism of tryptophan, Griggio et al (1967).
Chemical Abstracts 111 (24):219114j; Sunscreens and skin-lightening cosmetics containing kynurenines; Narutomi, et al. (1989).
Chemical Abstracts 92 (5):36767u; The mechanism of Kynurenine hydrolysis catalyzed by kynureninase, Tanizawa, et al. (1980).
Chemical Abstracts 97(15):125986k; Halogenoanthranyloylalanines as sweeteners; Tanabe (1982).
Chemical Abstracts 93(25):239866u; An intensely sweet analog of kynurenine; Kawashima, et al. (1980).
Chemical Abstracts, 109:48451u (1988).
Chemical Abstracts, 106:207831z (1987).
Chemical Abstracts, 72:30438c (1970).
Chemical Abstracts, 83:131913m (1975).
Chemical Abstracts, 83:114922w (1975).
Chemical Abstracts, 96: 115515w (1982).
10-Microbia Biochem, vol. 112, 1990, Abstract No. 135860g.
Kynurenine metabolites of tryptophan: Implications for neurologic diseases; Freese, et al, 40, Neurology 691-695; Apr. 1990.
Chemical Abstracts 106: 78724r (1987).
Chemical Abstracts 95: 55548b (1981).
Baron Bruce M.
McDonald Ian A.
Palfreyman Michael G.
Salituro Francesco G.
Schwarcz Robert
Dixon J. Michael
Merrell Dow Pharmaceuticals Inc.
Springer David B.
LandOfFree
NMDA antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with NMDA antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and NMDA antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2013904